FIELD: medicine.
SUBSTANCE: group of inventions refers to new arrangements of treating patients with ankylosing spondylitis and with psoriatic arthritis, usage of therapeutically effective amount of IL-17-antibody (for example, secukinumab) weekly introduced subcutaneously, and then monthly.
EFFECT: group of inventions is effective in treating patients with ankylosing spondylitis and with psoriatic arthritis.
21 cl, 18 dwg, 13 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF IL-17 ANTAGONISTS FOR INHIBITION OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS | 2015 |
|
RU2697383C2 |
| METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLARTHRITIS BY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | 2016 |
|
RU2728710C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2591083C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2665954C1 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHOD OF TREATING JOINT INJURIES | 2006 |
|
RU2457860C2 |
| NOVEL APPLICATION OF IL-1β COMPOUNDS | 2012 |
|
RU2571563C2 |
| METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING IL-4R ANTAGONIST | 2014 |
|
RU2674680C2 |
| METHODS FOR TREATMENT USING ANTI-IL-17A ANTIBODIES | 2016 |
|
RU2754683C2 |
